Official Title: A Phase II Evaluation of Ixabepilone BMS-247550 NCI-Supplied Agent NSC 710428 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: COMPLETED
Status Verified Date: 2019-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Drugs used in chemotherapy such as ixabepilone work in different ways to stop tumor cells from dividing so they stop growing or die This phase II trial is studying how well ixabepilone works in treating patients with recurrent or persistent endometrial cancer
Detailed Description: PRIMARY OBJECTIVES
I Determine the response rate in patients with recurrent or persistent endometrial adenocarcinoma treated with ixabepilone
II Determine the nature and degree of toxicity of this drug in these patients
OUTLINE This is a multicenter study
Patients receive ixabepilone IV over 3 hours on day 1 Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
PROJECTED ACCRUAL A total of 19-51 patients will be accrued for this study within 25 years